The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose The occurrence pattern of immune-related adverse events (irAEs) induced by immune checkpoint inhibitor (ICI) in cancer treatment remains unclear. Materials and Methods Phase II-III clinical trials that evaluated ICI-based treatments in cancer and were published between January 2007 and December 2019 were retrieved from public electronic databases. The pooled median time to onset (PMT-O), resolution (PMT-R), and immune-modulation resolution (PMT-IMR) of irAEs were generated using the metamedian package of R software.Results Twenty-two eligible studies involving 23 clinical trials and 8,436 patients were included. The PMT-O of all-grade irAEs ranged from 2.2 to 14.8 weeks, with the longest in renal events. The PMT-O of grade ≥ 3 irAEs was significantly longer than that of all-grade irAEs induced by programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) inhibitors (27.5 weeks vs. 8.4 weeks, p < 0.001) and treatment of nivolumab (NIV) plus ipilimumab (IPI) (7.9 weeks vs. 6.0 weeks, p < 0.001). The PMT-R of all-grade irAEs ranged from 0.1 to 54.3 weeks, with the shortest and longest in hypersensitivity/infusion reaction and endocrine events, respectively. The PMT-IMR of grade ≥ 3 irAEs was significantly shorter than that of all-grade irAEs caused by PD-1/PD-L1 blockade (6.9 weeks vs. 40.6 weeks, p=0.002) and NIV+IPI treatment (3.1 weeks vs. 5.9 weeks, p=0.031).Conclusion This study revealed the general and specific occurrence pattern of ICI-induced irAEs in pan-cancers, which was deemed to aid the comprehensive understanding, timely detection, and effective management of ICI-induced irAEs.
Abstract
Purpose The occurrence pattern of immune-related adverse events (irAEs) induced by immune checkpoint inhibitor (ICI) in cancer treatment remains unclear. Materials and Methods Phase II-III clinical trials that evaluated ICI-based treatments in cancer and were published between January 2007 and December 2019 were retrieved from public electronic databases. The pooled median time to onset (PMT-O), resolution (PMT-R), and immune-modulation resolution (PMT-IMR) of irAEs were generated using the metamedian package of R software.Results Twenty-two eligible studies involving 23 clinical trials and 8,436 patients were included. The PMT-O of all-grade irAEs ranged from 2.2 to 14.8 weeks, with the longest in renal events. The PMT-O of grade ≥ 3 irAEs was significantly longer than that of all-grade irAEs induced by programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) inhibitors (27.5 weeks vs. 8.4 weeks, p < 0.001) and treatment of nivolumab (NIV) plus ipilimumab (IPI) (7.9 weeks vs. 6.0 weeks, p < 0.001). The PMT-R of all-grade irAEs ranged from 0.1 to 54.3 weeks, with the shortest and longest in hypersensitivity/infusion reaction and endocrine events, respectively. The PMT-IMR of grade ≥ 3 irAEs was significantly shorter than that of all-grade irAEs caused by PD-1/PD-L1 blockade (6.9 weeks vs. 40.6 weeks, p=0.002) and NIV+IPI treatment (3.1 weeks vs. 5.9 weeks, p=0.031).Conclusion This study revealed the general and specific occurrence pattern of ICI-induced irAEs in pan-cancers, which was deemed to aid the comprehensive understanding, timely detection, and effective management of ICI-induced irAEs.
참고문헌 (52)
- Jain A, "Awakening immunity against cancer : a 2017 primer for clinicians", Chin J Cancer, 36, pp.67~ (2017)
- Hodi FS, "Improved survival with ipilimumab in patients with metastatic melanoma", N Engl J Med, 363, pp.711~723 (2010)
- Brahmer J, "Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer", N Engl J Med, 373, pp.123~135 (2015)
- McDermott DF, "Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab", J Clin Oncol, 33, pp.2013~2020 (2015)
- 임선민, "Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea", Cancer Research and Treatment, 52(4), pp.1112~1119 (2020), 대한암학회[DOI]
- Weber JS, "Safety profile of nivolumab monotherapy : a pooled analysis of patients with advanced melanoma", J Clin Oncol, 35, pp.785~792 (2017)
- Weber JS, "Toxicities of immunotherapy for the practitioner", J Clin Oncol, 33, pp.2092~2099 (2015)
- Johnson DB, "Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma", J Clin Oncol, 33, pp.e122~4 (2015)
- Liao B, "Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma", Neuro Oncol, 16, pp.589~593 (2014)
- Moslehi JJ, "Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis", Lancet, 391, pp.933~ (2018)
- Salem JE, "Cardiovascular toxicities associated with immune checkpoint inhibitors : an observational, retrospective, pharmacovigilance study", Lancet Oncol, 19, pp.1579~1589 (2018)
- "NCCN Clinical Practice Guidelines in Oncology, version 1" (2020)[URL]
- Haanen J, "Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 28, pp.iv119~iv142 (2017)
- Xu C, "Comparative safety of immune checkpoint inhibitors in cancer:systematic review and network meta-analysis", BMJ, 363, pp.k4226~ (2018)
- Martins F, "Adverse effects of immune-checkpoint inhibitors : epidemiology, management and surveillance", Nat Rev Clin Oncol, 16, pp.563~580 (2019)
- Weber JS, "Management of immunerelated adverse events and kinetics of response with ipilimumab", J Clin Oncol, 30, pp.2691~2697 (2012)
- "Common Terminology Criteria for Adverse Events version 5.0" (2017)[URL]
- Cumpston M, "Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions", Cochrane Database Syst Rev, 10, pp.ED000142~ (2019)
- Jadad AR, "Assessing the quality of reports of randomized clinical trials: is blinding necessary?", Control Clin Trials, 17, pp.1~12 (1996)
- McGrath S, "Onesample aggregate data meta-analysis of medians", Stat Med, 38, pp.969~984 (2019)
- Weber JS, "Patterns of onset and resolution of immunerelated adverse events of special interest with ipilimumab : detailed safety analysis from a phase 3 trial in patients with advanced melanoma", Cancer, 119, pp.1675~1682 (2013)
- Kwon ED, "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy(CA184-043) : a multicentre, randomised, double-blind, phase 3 trial", Lancet Oncol, 15, pp.700~712 (2014)
- Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
- Eggermont AM, "Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy", N Engl J Med, 375, pp.1845~1855 (2016)
- Reck M, "Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer", J Clin Oncol, 34, pp.3740~3748 (2016)
- Ascierto PA, "Ipilimumab 10 mg", kg versus ipilimumab 3 mg, Lancet Oncol, pp.2017, 18[DOI]
- Weber J, "Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma", N Engl J Med, 377, pp.1824~1835 (2017)
- Larkin J, "Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037 : a randomized, controlled, openlabel phase III trial", J Clin Oncol, 36, pp.383~390 (2018)
- Govindan R, "Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer", J Clin Oncol, 35, pp.3449~3457 (2017)
- Horn L, "Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer : twoyear outcomes from two randomized, open-label, phase III trials(CheckMate 017 and CheckMate 057)", J Clin Oncol, 35, pp.3924~3933 (2017)
- Armand P, "Nivolumab for relapsed", refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation : extended follow-up of the multicohort singlearm phase II CheckMate 205 trial, 2018, pp.36, 1428~1439
- Kelly K, "Safety profile of avelumab in patients with advanced solid tumors : a pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials", Cancer, 124, pp.2010~2017 (2018)
- Fradet Y, "Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer : results of >2 years of follow-up", Ann Oncol, 30, pp.970~976 (2019)
- Larkin J, "Five-year survival with combined nivolumab and ipilimumab in advanced melanoma", N Engl J Med, 381, pp.1535~1546 (2019)
- Geoerger B, "Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma(KEYNOTE-051) : interim analysis of an open-label, single-arm, phase 1-2 trial", Lancet Oncol, 21, pp.121~133 (2020)
- Carneiro BA, "Nivolumab in metastatic adrenocortical carcinoma : results of a phase 2 trial", J Clin Endocrinol Metab, 104, pp.6193~6200 (2019)
- Horinouchi H, "Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer : pooled analysis of ONO-4538-05 and ONO-4538-06 studies", Cancer Med, 8, pp.5183~5193 (2019)
- Lebbe C, "Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma : results from the phase IIIb", IV CheckMate 511 trial, 2019, pp.37, 867~875
- Morse MA, "Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high", mismatch repair-deficient metastatic colorectal cancer, 2019, pp.24, 1453~1461
- Sharma P, "Efficacy and tolerability of tremelimumab in locally advanced or metastatic urothelial carcinoma patients who have failed first-line platinum-based chemotherapy", Clin Cancer Res, 26, pp.61~70 (2020)
- Tomita Y, "Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma : analysis of Japanese patients in CheckMate 214 with extended follow-up", Jpn J Clin Oncol, 50, pp.12~19 (2020)
- De Velasco G, "Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1", PD-L1 inhibitors in cancer patients, 2017, pp.5, 312~318
- Minkis K, "The risk of rash associated with ipilimumab in patients with cancer : a systematic review of the literature and meta-analysis", J Am Acad Dermatol, 69, pp.e121~8 (2013)
- Tarhini A, "Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy : the underlying mechanisms and clinical management", Scientifica(Cairo), 2013, pp.857519~ (2013)
- Baxi S, "Immune-related adverse events for anti-PD-1 and antiPD-L1 drugs : systematic review and meta-analysis", BMJ, 360, pp.k793~ (2018)
- Almutairi AR, "Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma : a systematic review and meta-analysis", Front Oncol, 10, pp.91~ (2020)
- Wolchok JD, "Ipilimumab monotherapy in patients with pretreated advanced melanoma : a randomised, double-blind, multicentre, phase 2, dose-ranging study", Lancet Oncol, 11, pp.155~164 (2010)
- Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N Engl J Med, 366, pp.2443~2454 (2012)
- Hassel JC, "Combined immune checkpoint blockade(anti-PD-1", anti-CTLA-4) : evaluation and management of adverse drug reactions, 2017, pp.57, 36~49
- Goldinger SM, "Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy", Clin Cancer Res, 22, pp.4023~4029 (2016)
- Kahler KC, "Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma", J Dtsch Dermatol Ges, 14, pp.662~681 (2016)
- Freeman-Keller M, "Anti-programmed death receptor 1 immunotherapy in melanoma : rationale, evidence and clinical potential", Ther Adv Med Oncol, 7, pp.12~21 (2015)